Pharsight

1. List of Durysta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629185	ALLERGAN INC	7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof	Jul, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707	ALLERGAN INC	Hypotensive lipid-containing biodegradable intraocular implants and related implants	Apr, 2024 (1 year, 2 months from now)
US8673341	ALLERGAN INC	Intraocular pressure reduction with intracameral bimatoprost implants	Feb, 2025 (2 years from now)
US9149428	ALLERGAN INC	Processes for making cyclic lipid implants for intraocular use	Dec, 2026 (3 years from now)
US10441543	ALLERGAN INC	Processes for making cyclic lipid implants for intraocular use	Dec, 2026 (3 years from now)
US8206737	ALLERGAN INC	Hypotensive lipid-containing biodegradable intraocular implants and related methods	Apr, 2027 (4 years from now)
US7799336	ALLERGAN INC	Hypotensive lipid-containing biodegradable intraocular implants and related methods	Apr, 2029 (6 years from now)
US9492316	ALLERGAN INC	Prostamide-containing intraocular implants and methods of use thereof	Oct, 2034 (11 years from now)
US9980974	ALLERGAN INC	Prostamide-containing intraocular implants and methods of use thereof	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 4, 2023

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

Strength	Dosage	Availability
10MCG	IMPLANT;OPHTHALMIC	Prescription

2. List of Latisse drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8038988	ALLERGAN	Method of enhancing hair growth	Aug, 2023 (6 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8986715	ALLERGAN	Method of enhancing hair growth	Jan, 2023 (23 days ago)
US9226931	ALLERGAN	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	Jan, 2023 (23 days ago)
US8632760	ALLERGAN	Method of enhancing hair growth	Jan, 2023 (23 days ago)
US8263054	ALLERGAN	Method of enhancing hair growth	Jan, 2023 (23 days ago)
US8758733	ALLERGAN	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	Jan, 2023 (23 days ago)
US9216183	ALLERGAN	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	Jan, 2023 (23 days ago)
US8101161	ALLERGAN	Method of enhancing hair growth	May, 2024 (1 year, 3 months from now)

Market Authorisation Date: 24 December, 2008

Treatment: Method of increasing hair growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of stimulating hair growth; Treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness

Dosage: SOLUTION/DROPS;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0003	03 May, 2010	1	01 Dec, 2014	25 May, 2024	Extinguished Deferred

Strength	Dosage	Availability
0.03%	SOLUTION/DROPS;TOPICAL	Prescription

3. List of Lumigan drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Jun, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8278353	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US8772338	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US8309605	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US8586630	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US8524777	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US9155716	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US8338479	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US8299118	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US9241918	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US8933120	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)
US8933127	ALLERGAN	Enhanced bimatoprost ophthalmic solution	Mar, 2025 (2 years from now)

Market Authorisation Date: 31 August, 2010

Treatment: A method of lowering intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; Method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC